title: Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model.
abstract: The APP[V717I] London (APP-Ld) mouse model recapitulates important pathological and clinical hallmarks of Alzheimer's disease (AD) and is therefore a valuable paradigm for evaluating therapeutic candidates. Historically, both the parenchymal and vascular amyloid deposits, and more recently, truncated and pyroglutamate-modified Abeta(3(pE)-42) species, are perceived as important hallmarks of AD-pathology. Late stage symptoms are preceded by robust deficits in orientation and memory that correlate in time with Abeta oligomerization and GSK3β-mediated phosphorylation of endogenous murine Tau, all markers that have gained considerable interest during the last decade. Clinical parallels with AD patients and the value of the APP-Ld transgenic mouse model for preclinical in vivo testing of candidate drugs are discussed.
authors.affiliation: reMYND NV, Gaston Geenslaan 1, 3001 Heverlee-Leuven, Belgium.
authors.forename: An
authors.initials: A
authors.lastname: Tanghe
authors.forename: Annelies
authors.initials: A
authors.lastname: Termont
authors.forename: Pascal
authors.initials: P
authors.lastname: Merchiers
authors.forename: Stephan
authors.initials: S
authors.lastname: Schilling
authors.forename: Hans-Ulrich
authors.initials: HU
authors.lastname: Demuth
authors.forename: Louise
authors.initials: L
authors.lastname: Scrocchi
authors.forename: Fred
authors.initials: F
authors.lastname: Van Leuven
authors.forename: Gerard
authors.initials: G
authors.lastname: Griffioen
authors.forename: Tom
authors.initials: T
authors.lastname: Van Dooren